Léon C, Freund M, Ravanat C, Baurand A, Cazenave J P, Gachet C
Institut National de la Santé et de la Recherche Médicale U.311, Etablissement Français du Sang-Alsace, Strasbourg, France.
Circulation. 2001 Feb 6;103(5):718-23. doi: 10.1161/01.cir.103.5.718.
ADP plays a key role in hemostasis, acting through 2 platelet receptors: the P2Y(1) receptor and an unidentified P2 receptor, called P2cyc, coupled to adenylyl cyclase inhibition, which is the target of the antiplatelet drug clopidogrel. We showed that the P2Y(1) receptor is an essential cofactor in thrombotic states induced by intravenous infusion of collagen and epinephrine. The aim of the present study was to assess the role of this receptor in thrombin-dependent tissue factor-induced thromboembolism.
Human thromboplastin was injected intravenously into wild-type or P2Y(1)-deficient mice, and the effects on platelet count and mortality were determined and plasma thrombin-antithrombin III (TAT) complexes were quantified. P2Y(1)-deficient mice were resistant to the thromboembolism induced by injection of thromboplastin. Whereas the platelet count decreased sharply in wild-type mice, there was no significant drop in platelets in P2Y(1)-knockout mice. The platelet consumption in wild-type mice was probably due to thrombin generation, because it was abolished by hirudin. Thromboplastin also led to a rise in TAT complexes in plasma, again reflecting thrombin formation. This effect, however, was less important in P2Y(1)-knockout mice than in wild-type mice, indicating that less thrombin was generated in the absence of P2Y(1). Similar results were obtained after intravenous administration of N:(6)-methyl-2'-deoxyadenosine-3':5'-bisphosphate, a selective antagonist of the P2Y(1) receptor, to wild-type mice.
Our results demonstrate a role of the P2Y(1) receptor in thrombotic states involving thrombin generation and provide further evidence for the potential relevance of this receptor as a target for antithrombotic drugs.
ADP在止血过程中发挥关键作用,通过两种血小板受体起作用:P2Y(1)受体和一种未明确的P2受体(称为P2cyc),后者与腺苷酸环化酶抑制偶联,是抗血小板药物氯吡格雷的作用靶点。我们发现P2Y(1)受体是静脉输注胶原蛋白和肾上腺素诱导的血栓形成状态中的必需辅助因子。本研究的目的是评估该受体在凝血酶依赖性组织因子诱导的血栓栓塞中的作用。
将人凝血活酶静脉注射到野生型或P2Y(1)基因缺陷小鼠体内,测定对血小板计数和死亡率的影响,并对血浆凝血酶 - 抗凝血酶III(TAT)复合物进行定量。P2Y(1)基因缺陷小鼠对注射凝血活酶诱导的血栓栓塞具有抗性。野生型小鼠的血小板计数急剧下降,而P2Y(1)基因敲除小鼠的血小板没有明显下降。野生型小鼠的血小板消耗可能是由于凝血酶生成,因为水蛭素可消除这种消耗。凝血活酶还导致血浆中TAT复合物升高,再次反映了凝血酶的形成。然而,这种作用在P2Y(1)基因敲除小鼠中比在野生型小鼠中更弱,表明在缺乏P2Y(1)的情况下生成的凝血酶较少。对野生型小鼠静脉注射P2Y(1)受体的选择性拮抗剂N6 - 甲基 - 2'-脱氧腺苷 - 3':5'-双磷酸后,得到了类似的结果。
我们的结果证明了P2Y(1)受体在涉及凝血酶生成的血栓形成状态中的作用,并为该受体作为抗血栓药物靶点的潜在相关性提供了进一步证据。